Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery
MINNEAPOLIS, Minn., January 7, 2025 – Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the...
MINNEAPOLIS, Minn., January 7, 2025 – Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the...
